{"pageContent": "Background: In the past years, there has been significant progress in anticancer drug development for patients with metastatic castration-resistant prostate cancer (CRPC). However, the current instruments to assess clinical treatment response have limitations and may not sufficiently reflect patient benefit. Our objective was to systematically identify tools to evaluate both patient benefit and clinical anticancer-treatment response as basis for an international consensus process and development of a specific pragmatic instrument for men with CRPC.", "metaData": {"source": "Endocrine disruptors and prostate cancer\nhttps://pubmed.ncbi.nlm.nih.gov/28422034/"}}